Vasculitis & polymyalgia rheumatica
Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts
Study context
- Population
- Adults with PMR49 and 47 completed each period
- Comparison
- Clofutriben with prednisolone 10, 15, 20 or 30 mg/d vs prednisolone 10 mg/d with placebo
- Outcome
- Clinical relapse
Methodological detailssingle-blind
- Single-blind
Main finding
As reported in the abstract
Prednisolone 10 mg/d + clofutriben
5
events
Further findings
- More severe symptoms and physical disability with prednisolone 10 or 15 mg/d, but not 20 or 30 mg/d, given with clofutriben; inflammatory biomarkers followed a similar pattern
Safety
- Across all prednisolone doses, clofutriben mitigated GC-related adverse effects on biomarkers of bone turnover, lipid metabolism, hypercoagulability, and CV and adrenal function
Original publication
Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts. Ann Rheum Dis. Published 11 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →